Taiwanese Journal of Obstetrics and Gynecology
Volume 44, Issue 3 , Pages 209-217 , September 2005

Mechanisms Involved in Chemoresistance in Ovarian Cancer

  • Fu-Shing Liu

      Affiliations

    • Department of Obstetrics and Gynecology, Taichung Veterans General Hospital, Taichung, Taiwan
    • Corresponding Author InformationCorrespondence to: Dr. Fu-Shing Liu, Department of Obstetrics and Gynecology, Taichung Veterans General Hospital, 160, Section 3, Chung-Kang Road, Taichung, Taiwan

Received 11 July 2005 ,Revised 13 July 2005 ,Accepted 14 July 2005.

References 

  1. McGuire WP , Ozols RF . Chemotherapy of advanced ovarian cancer . Semin Oncol . 1998;25:340–348
  2. Ozols R . Treatment of gynecologic cancer: the US experience . Tumori . 1999;85:S5–11
  3. el-Deiry WS . Role of oncogenes in resistance and killing by cancer therapeutic agents . Curr Opin Oncol . 1997;9:79–87
  4. Gottesman MM , Fojo T , Bates SE . Multidrug resistance in cancer: role of ATP-dependent transporters . Nat Rev Cancer . 2002;2:48–58
  5. Joncourt F , Buser K , Altermatt H , Bacchi M , Oberli A , Cerny T . Multiple drug resistance parameter expression in ovarian cancer . Gynecol Oncol . 1998;70:176–182
  6. Perek N , Denoyer D . The multidrug resistance mechanisms and their interactions with the radiopharmaceutical probes used for an in vivo detection . Curr Drug Metab . 2002;3:97–113
  7. Grant CE , Kurz EU , Cole SP , Deeley RG . Analysis of the intron-exon organization of the human multidrug-resistance protein gene (MRP) and alternative splicing of its mRNA . Genomics . 1997;45:368–378
  8. Cole SP , Bhardwaj G , Gerlach JH , et al.   Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line . Science . 1992;258:1650–1654
  9. Zaman GJ , Versantvoort CH , Smit JJ , et al.   Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines . Cancer Res . 1993;53:1747–1750
  10. Schneider E , Horton JK , Yang CH , Nakagawa M , Cowan KH . Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance . Cancer Res . 1994;54:152–158
  11. Zaman GJ , Flens MJ , van Leusden MR , et al.   The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump . Proc Natl Acad Sci USA . 1994;91:8822–8826
  12. Grant CE , Valdimarsson G , Hipfner DR , Almquist KC , Cole SP , Deeley RG . Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs . Cancer Res . 1994;54:357–361
  13. Cole SP , Sparks KE , Fraser K , et al.   Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells . Cancer Res . 1994;54:5902–5910
  14. He X , Ee PL , Coon JS , Beck WT . Alternative splicing of the multidrug resistance protein 1/ATP binding cassette transporter subfamily gene in ovarian cancer creates functional splice variants and is associated with increased expression of the splicing factors PTB and SRp20 . Clin Cancer Res . 2004;10:4652–4660
  15. Seiden MV , Swenerton KD , Matulonis U , et al.   A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy . Gynecol Oncol . 2002;86:302–310
  16. Chaudhary PM , Roninson IB . Activation of MDR1 (P- glycoprotein) gene expression in human cells by protein kinase C agonists . Oncol Res . 1992;4:281–290
  17. Hannon GJ . RNA interference . Nature . 2002;418:244–251
  18. Fjose A , Ellingsen S , Wargelius A , Seo HC . RNA interference: mechanisms and applications . Biotechnol Annu Rev . 2001;7:31–57
  19. Duan Z , Brakora KA , Seiden MV . Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells . Mol Cancer Ther . 2004;3:833–838
  20. Wu H , Hait WN , Yang JM . Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells . Cancer Res . 2003;63:1515–1519
  21. Rebbeck TR . Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility . Cancer Epidemiol Biomarkers Prev . 1997;6:733–743
  22. Blackburn AC , Woollatt E , Sutherland GR , Board PG . Characterization and chromosome location of the gene GSTZ1 encoding the human zeta class glutathione transferase and maleylacetoacetate isomerase . Cytogenet Cell Genet . 1998;83:109–114
  23. Board PG , Coggan M , Chelvanayagam G , et al.   Identification, characterization, and crystal structure of the omega class glutathione transferases . J Biol Chem . 2000;275:24798–24806
  24. Lewis AD , Hayes JD , Wolf CR . Glutathione and glutathione dependent enzymes in ovarian adenocarcinoma cell lines derived from a patient before and after the onset of drug resistance: intrinsic differences and cell cycle effects . Carcinogenesis . 1988;9:1283–1287
  25. Smith M , Evans C , Doane-Setzer P , Castro V . Denitrosation of 1,3 bis (2-chloroethyl)-1-nitrosourea by class mu glutathione transferases and its role in cellular resistance in rat brain tumor cells . Cancer Res . 1989;49:2621–2625
  26. Black SM , Beggs JD , Hayes JD , Murarratsu M , Sakai M , Wolfe CR . Expression of human glutathione S-transferase in S. cerevisiae confers resistance to the anticancer drugs adriamycin and chlorambucil . Biochem J . 1990;268:309–315
  27. Coughlin SS , Hall IJ . Glutathione S-transferase polymorphisms and risk of ovarian cancer: a huge review . Genet Med . 2002;4:250–257
  28. Ferrandina G , Scambia G , Damia G , et al.   Glutathione S- transferase activity in epithelial ovarian cancer: association with response to chemotherapy and disease outcome . Ann Oncol . 1997;8:343–350
  29. Sarhanis P , Redman C , Perrett C , et al.   Epithelial ovarian cancer: influence of polymorphism at the glutathione S- transferase GSTM1 and GSTT1 loci on p53 expression . Br J Cancer . 1996;74:1757–1761
  30. Green JA , Robertson LJ , Clark AH . Glutathione S-transferase expression in benign and malignant ovarian tumors . Br J Cancer . 1993;68:235–239
  31. Cherian MG , Jayasurya A , Bay BH . Metallothioneins in human tumors and potential roles in carcinogenesis . Mutat Res . 2003;533:201–209
  32. Jordan MA , Toso RJ , Thrower D , Wilson L . Mechanism of mitotic block and inhibition of cell proliferation by Taxol at low concentrations . Proc Natl Acad Sci USA . 1993;90:9552–9556
  33. Kavallaris M , Kuo DY , Burkhart CA , et al.   Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes . J Clin Invest . 1997;100:1282–1293
  34. Giannakakou P , Sackett DL , Kang YK , et al.   Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization . J Biol Chem . 1997;272:17118–17125
  35. Monzo M , Rosell R , Sanchez JJ , et al.   Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations . J Clin Oncol . 1999;17:1786–1793
  36. Tsurutani J , Komiya T , Uejima H , et al.   Mutational analysis of the beta-tubulin gene in lung cancer . Lung Cancer . 2002;35:11–16
  37. Sale S , Sung R , Shen P , et al.   Conservation of the class I {beta}-tubulin gene in human populations and lack of mutations in lung cancers and paclitaxel-resistant ovarian cancers . Mol Cancer Ther . 2002;1:215–225
  38. Nicoletti MI , Valoti G , Giannakakou P , et al.   Expression of beta-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCI-Anticancer Drug Screen: correlation with sensitivity to microtubule active agents . Clin Cancer Res . 2001;7:2912–2922
  39. Holden JA . Human deoxyribonucleic acid topoisomerases: molecular targets of anticancer drugs . Ann Clin Lab Science . 1997;27:402–411
  40. Guinee DG , Holden JA , Benfield JR , et al.   Comparison of DNA topoisomerase II alpha expression in small cell and nonsmall cell carcinoma of the lung. In search of a mechanism of chemotherapeutic response . Cancer . 1996;78:729–735
  41. Lynch BJ , Guinee DG , Holden JA . Human DNA topoisomerase II-alpha: a new marker of cell proliferation in invasive breast cancer . Hum Pathol . 1997;28:1180–1188
  42. Iino K, Sasano H, Yabuki N, Oki Y, Kikuchi A, Yoshimi T, et al. DNA topoisomerase II and Ki-67 in human adrenocortical neoplasms: a possible marker of differentiation between adenomas and carcinomas . Mod Pathol . 1997;10:901–907
  43. Kellner U , Sehested M , Jensen P , et al.   Culprit and victim-DNA topoisomerase II . Lancet Oncol . 2002;3:235–243
  44. Pommier Y . DNA topoisomerase I and II in cancer chemotherapy: update and perspectives . Cancer Chemother Pharmacol . 1993;32:103–108
  45. Masuda H , Tanaka T , Matsuda H , Kusaba I . Increased removal of DNA-bound platinum in a human ovarian cancer cell line resistant to cis-diamminedichloroplatinum (II) . Cancer Res . 1990;50:1863–1866
  46. Parker RJ , Eastman A , Bostick-Bruton F , Reed E . Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation . J Clin Invest . 1991;87:772–777
  47. Zhen W , Link CJ , O'Connor PM , et al.   Increased genespecific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines . Mol Cell Biol . 1992;12:3689–3698
  48. Johnson SW, Perez RP, Godwin AK, Yeung AT, Handel LM, Ozols RF, et al. Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines . Biochem Pharmacol . 1994;47:689–697
  49. Ferry KV , Hamilton TC , Johnson SW . Increased nucleotide excision repair in cisplatin resistant ovarian cancer cells . Biochem Pharmacol . 2000;60:1305–1313
  50. Wood RD . Nucleotide excision repair in mammalian cells . J Biol Chem . 1997;272:23465–23468
  51. Fraser M , Leung B , Jahani-Asl A , Yan X , Thompson WE , Tsang BK . Chemoresistance in human ovarian cancer: the role of apoptotic regulators . Reprod Biol Endocrinol . 2003;1:66
  52. Yuan ZQ , Sun M , Feldman RI , et al.   Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer . Oncogene . 2000;19:2324–2330
  53. Lasky T , Silbergeld E . P53 mutations associated with breast, colorectal, liver, lung, and ovarian cancers . Environ Health Perspect . 1996;104:1324–1331
  54. Gatti L , Supino R , Perego P , et al.   Apoptosis and growth arrest induced by platinum compounds in U2-OS cells reflect a specific DNA damage recognition associated with a different p53-mediated response . Cell Death Differ . 2002;9:1352–1359
  55. Servidei T , Ferlini C , Riccardi A , et al.   The novel trinuclear platinum complex BBR3464 induces a cellular response different from cisplatin . Eur J Cancer . 2001;37:930–938
  56. Schneiderman D , Kim J-M , Senterman M , Tsang BK . Sustained suppression of Fas ligand expression in cisplatin-resistant human ovarian surface epithelial cancer cells . Apoptosis . 1999;4:271–282
  57. Li J , Feng Q , Kim JM , et al.   Human ovarian cancer and cisplatin resistance: possible role of inhibitor of apoptosis proteins . Endocrinology . 2001;142:370–380
  58. Mansouri A , Zhang Q , Ridgway LD , Tian L , Claret FX . Cisplatin resistance in an ovarian carcinoma is associated with a defect in programmed cell death control through XIAP regulation . Oncol Res . 2003;13:399–404
  59. Robertson JD , Orrenius S , Zhivotovsky B . Review: nuclear events in apoptosis . J Struct Biol . 2000;129:346–358
  60. Daugas E, Nochy D, Ravagnan L, Loeffler M, Susin SA, Zamzami N, et al. Apoptosis inducing factor: an ubiquitous mitochondrial oxidoreductase involved in apoptosis regulation . FEBS Lett . 2000;476:118–123
  61. Ahn HJ , Kim YS , Kim JU , Han SM , Shin JW , Yang HO . Mechanism of Taxol-induced apoptosis in human SKOV3 ovarian carcinoma cells . J Cellular Biochem . 2004;91:1043–1052
  62. Jesenberger V , Jentsch S . Deadly encounter: ubiquitin meets apoptosis . Nat Rev Mol Cell Biol . 2002;3:112–121
  63. Verhagen AM , Coulson EJ , Vaux DL . Inhibitor of apoptosis proteins and their relatives: IAPs and other BIRPs . Genome Biol . 2001;2:3009; 1-reviews3009.10.
  64. Deveraux QL , Takahashi R , Salvesen GS , Reed JC . X-linked IAP is a direct inhibitor of cell-death proteases . Nature . 1997;388:300–304
  65. Sasaki H , Sheng Y , Kotsuji F , Tsang BK . Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells . Cancer Res . 2000;60:5659–5666
  66. Krammer PH . CD95's deadly mission in the immune system . Nature . 2000;407:789–795
  67. Meng Y , Kang S , So J , Reierstad S , Fishman DA . Translocation of Fas by LPA prevents ovarian cancer cells from anti-Fas-induced apoptosis . Gynecol Oncol . 2005;96:462–469
  68. Ashkenazi A , Dixit VM . Death receptors: signaling and modulation . Science . 1998;281:1305–1308
  69. Uslu R , Jewett A , Bonavida B . Sensitization of human ovarian tumor cells by subtoxic CDDP to anti-fas antibody-mediated cytotoxicity and apoptosis . Gynecol Oncol . 1996;62:282–291
  70. Irmler M , Thome M , Hahne M , et al.   Inhibition of death receptor signals by cellular FLIP . Nature . 1997;388:190–195
  71. Srinivasula SM , Ahmad M , Lin JH , et al.   CLAP, a novel caspase recruitment domain-containing protein in the tumor necrosis factor receptor pathway, regulates NF-kappaB activation and apoptosis . J Biol Chem . 1999;274:17946–17954
  72. Hassan MI , Kassim SK , Saeda L , Laban M , Khalifa A . Ovarian cancer-induced immunosuppression: relationship to tumor necrosis factor-alpha (TNF-alpha) release from ovarian tissue . Anticancer Res . 1999;19:5657–5662
  73. Naylor MS , Stamp GW , Foulkes WD , Eccles D , Balkwill FR . Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression . J Clin Invest . 1993;91:2194–2206
  74. Xiao CW , Yan X , Li Y , Reddy SA , Tsang BK . Resistance of human ovarian cancer cells to tumor necrosis factor alpha is a consequence of nuclear factor kappaB-mediated induction of Fas-associated death domain-like interleukin-1beta-converting enzyme-like inhibitory protein . Endocrinology . 2003;144:623–630
  75. Mezzanzanica D , Balladore E , Turatti F , et al.   CD95-mediated apoptosis is impaired at receptor level by cellular FLICE-inhibitory protein (long form) in wild-type p53 human ovarian carcinoma . Clin Cancer Res . 2004;10:5202–5214
  76. Samanta AK , Huang HJ , Bast RC , Liao WS . Overexpression of MEKK3 confers resistance to apoptosis through activation of NFkappaB . J Biol Chem . 2004;279:7576–7583
  77. Cheng JQ, Jiang X, Fraser M, Li M, Dan HC, Sun M, et al. Role of X-linked inhibitor of apoptosis protein in chemo-resistance in ovarian cancer: possible involvement of the phosphoinositide-3 kinase/Akt pathway . Drug Resist Updat . 2002;5:131–146
  78. Philp AJ , Campbell IG , Leet C , et al.   The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors . Cancer Res . 2001;61:7426–7429
  79. Fraser M , Leung BM , Yan X , Dan HC , Cheng JQ , Tsang BK . P53 is a determinant of Xiap/Akt-mediated chemoresistance in human ovarian cancer cells . Cancer Res . 2003;63:7081–7088
  80. Yuan ZQ , Feldman RI , Sussman GE , Coppola D , Nicosia SV , Cheng JQ . AKT2 inhibition of cisplatin-induced JNK/p38 and Bax activation by phosphorylation of ASK1: implication of AKT2 in chemoresistance . J Biol Chem . 2003;278:23432–23440
  81. Asselin E , Mills GB , Tsang BK . XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells . Cancer Res . 2001;61:1862–1868
  82. Brinkmann U , Brinkmann E , Gallo M , Scherf U , Pastan I . Role of CAS, human homologue to the yeast chromosome segregation gene CSE, in toxin and TNF mediated apoptosis . Biochemistry . 1996;35:6981–6999
  83. Brustmann H . Expression of cellular apoptosis susceptibility protein in serous ovarian carcinoma: a clinicopathologic and immunohistochemical study . Gynecol Oncol . 2004;92:268–276
  84. Ioffe OB , Papadimitriou JC , Drachenberg CB . Correlation of proliferative indices, apoptosis, and related oncogene expression (bcl-2 and c-erbB-2) and p53 in proliferative, hyperplastic, and malignant endometrium . Hum Pathol . 1998;29:1150–1159
  85. Krajewski S , Krajewska M , Shabaik A , et al.   Immunohisto-chemical analysis of in vivo patterns of bcl-x expression . Cancer Res . 1994;54:5501–5507
  86. Reed JC . Dysregulation of apoptosis in cancer . J Clin Oncol . 1999;17:2941–2953
  87. Yang X , Zheng F , Xing H , et al.   Resistance to chemotherapy-induced apoptosis via decreased caspase-3 activity and overexpression of antiapoptotic proteins in ovarian cancer . J Cancer Res Clin Oncol . 2004;130:423–428
  88. Vogelstein B , Lane D , Levine AJ . Surfing the p53 network . Nature . 2000;408:307–310

PII: S1028-4559(09)60143-1

doi: 10.1016/S1028-4559(09)60143-1

Taiwanese Journal of Obstetrics and Gynecology
Volume 44, Issue 3 , Pages 209-217 , September 2005

Article Tools